Texas Heart Institute Journal

History of Medicine

The Caged-Ball Prosthesis 60 Years Later: A Historical Review of a Cardiac Surgery Milestone

Andrea De Martino, MD[1]; Aldo D. Milano, MD, PhD[2]; Mila Della Barbera, MD[3]; Gaetano Thiene, MD[3]; Uberto Bortolotti, MD[1]

[1]Cardiothoracic and Vascular Department, University Hospital, Pisa, Italy
[2]Division of Cardiac Surgery, University of Bari, Bari, Italy
[3]Department of Cardiovascular Pathology, University of Padua, Padua, Italy

Sixty years ago, 2 cardiac operations dramatically influenced the survival of patients with valvular heart disease. The replacement of an aortic valve by Dwight Harken and of a mitral valve by Albert Starr with mechanical caged-ball valves, both in 1960, was a true milestone in the history of cardiac surgery and the beginning of a long journey toward prosthetic valve replacement full of expectations, hopes, and dreams fulfilled. Caged-ball prostheses underwent numerous modifications in design and materials to improve reliability and prevent specific mechanical and thrombogenic complications. Clinical and pathologic experience gained during the past 6 decades has enabled the development of safe, durable, and minimally thrombogenic mechanical prostheses. ***(Tex Heart Inst J 2022;49(2):e207267)***

Citation:
De Martino A, Milano AD, Della Barbera M, Thiene G, Bortolotti U. The caged-ball prosthesis 60 years later: a historical review of a cardiac surgery milestone. Tex Heart Inst J 2022;49(2):e207267. doi: 10.14503/THIJ-20-7267

Key words:
Aortic valve; biocompatible materials/history; heart valve prosthesis/history; history, 20th century; mitral valve; prosthesis design/history

Corresponding author:
Uberto Bortolotti, MD, Dipartimento Cardiotoracico e Vascolare, Azienda Ospedaliero Universitaria, Via Paradisa 2, 56124 Pisa, Italy

E-mail:
uberto.bortolotti@med.unipi.it

Just over 60 years ago, 2 historic operations performed within months of each other dramatically changed the survival outlook for patients with valvular heart disease. In March 1960, Dwight Harken performed the first aortic valve replacement (AVR); in September, Albert Starr performed the first mitral valve replacement (MVR).[1,2] The native valve in each case was replaced with a caged-ball mechanical prosthesis. So began the era of valvular surgery, which until then had been confined to attempts to relieve mitral stenosis by closed commissurotomy.[3] In this review, we trace the long journey from the first caged-ball valves to today's mechanical valves of various designs and materials.

Prologue

In 1951, Charles Hufnagel conceived a mechanical ball-valve based on a bottle stopper patented almost a century before.[4,5] Hufnagel's valve consisted of an inlet, an outlet, and between them a chamber containing a ball. Initially, the entire prosthesis was made of polymethyl methacrylate (Lucite); to reduce noise, Hufnagel later replaced the Lucite ball with a hollow, silicone rubber–covered ball. Hufnagel's goal was to develop a prosthetic valve that would treat aortic insufficiency while functioning satisfactorily within the cardiovascular system.[6] At the time, certain cardiac operations were done only on a beating heart under generally mild hypothermia or with use of cross-circulation as pioneered by C. Walton Lillehei.[7] Introduction of the heart-lung machine, which would make cardiopulmonary bypass (CPB) possible, was still one year away.[8] Repair or replacement of the ascending aorta had not yet been demonstrated. Others, however, had shown that the thoracic aorta could be temporarily and safely clamped during aortic coarctation repair.[9,10] In 1952, Hufnagel decided to implant his device with a sutureless fixation ring in the descending aorta of a 30-year-old woman who had aortic valve insufficiency.[4]

Functionally, the Hufnagel ball valve did not replace the AV, but assisted it by eliminating most aortic regurgitation. Many recipients of the valve showed short- and long-term clinical improvement.[7] In 1975, Fishbein and Roberts reviewed postoperative outcomes in 55 Hufnagel valve recipients, and observed that most deaths were unrelated to valvular dysfunction.[11] They concluded that the device could remain in

place even if the AV itself were replaced.[11] Eventually, more than 200 patients received the Hufnagel prosthesis.[12] The caged-ball concept was ready for development.

Caged-Ball Prostheses

Harken-Soroff Valve (1960)

In the first AVR, Harken implanted in the subcoronary position a prosthesis consisting of a stainless-steel double cage containing a silicone ball and an Ivalon (polyvinyl acetate) patch (Fig. 1).[12] The outer cage of the Harken-Soroff valve was designed to keep the ball from impinging on the aortic wall and possibly causing valve malfunction. Harken performed his AVR through a bilateral throracotomy with the patient under CPB, with cooling to 26 °C and left ventricular decompression through the left atrial auricle. A modified longitudinal aortotomy exposed the native AV for replacement with the prosthesis. Only one of the first 5 recipients of the Harken-Soroff valve survived.[1] The valve was used in fewer than 20 patients and was soon abandoned.

Starr-Edwards Valve (1960)

The first Starr-Edwards prosthesis, intended for MVR, consisted of a Lucite cage, a silicone rubber (Silastic) ball, and a Teflon sewing ring.[13] The valve failure rate in canine experiments was high, mainly because of valvular thrombosis.[14] Numerous design modifications followed.[15] Adding a Silastic shield to cover the valve suture line substantially reduced thrombus formation after MVR in dogs.[16] Nevertheless, Starr used his original design in the first successful MVR, in a 33-year-old woman.[2] This model was soon replaced by one comprising a metallic cage made of a cobalt-chromium-molybdenum-nickel alloy (Stellite), a Silastic ball, and a silicone rubber sponge in the sewing ring.[12] Later models were even less thrombogenic. Model 6120 had a cloth-covered inflow face and thinner cage struts. Model 6300 had an entirely cloth-covered cage and a hollow Stellite ball.

The aortic Starr-Edwards prostheses evolved in a similar way. A prototype designed with a 4-strut stainless-steel cage and a silicone ball was followed by 3-strut cage[12] and cloth-covered versions.

Despite their reduced thrombogenicity, the Starr-Edwards valves soon began to show increasingly frequent wear on cloth-covered orifices and struts.[17,18] This problem was dealt with in a new series of "track valves" consisting of an outer cage covered in thin polypropylene cloth and an inner cage with narrow bare metallic tracks meant to prevent contact between ball and fabric. Another frequent problem with early Starr-Edwards valves was ball variance, changes in ball size caused by physical and chemical alterations in the silicone.[19] In models manufactured up to 1965, lipid absorption and swelling led to ball grooving and fragmentation from contact with the cage and the possibility of embolization.[19] Curing the silicone rubber and heating the ball at high temperature before placing it in the cage resolved the problem.[20]

Worldwide, perhaps 175,000 or more Starr-Edwards prostheses were implanted until production ceased in the early 2000s (Fig. 2).[13,21,22] The device has proved extremely durable, lasting as long as 44 years after AVR and 51 years after MVR.[21-25]

Fig. 1 *Photograph shows a Harken-Soroff valve with a stainless-steel double cage and silicone ball.*

Reproduced with permission from the Museum of Medical History, Sierra Sacramento Valley Medical Society and the Bioengineering Department, California State University, Sacramento, California.

Fig. 2 *Photograph shows a Starr-Edwards valve, with a Stellite cage and a Silastic ball.*

Reproduced with permission from the National Museum of American History of the Smithsonian Institute, Washington, DC.

Pemco-Cartwright Valve (1961)

Introduced in 1961, the Pemco-Cartwright valve consisted of a 6-strut closed cage (later changed to an incomplete 4-strut cage), a Teflon-covered sewing ring, and a heat-cured Silastic ball (Fig. 3).[26,27] Little clinical information about this valve is available in the literature, suggesting that few were ever implanted. In 1961, the valve was used for combined AVR-MVR in a patient who survived approximately 4.5 months with excellent hemodynamic results.[26] In 1991, the Pemco-Cartwright prosthesis was mentioned by Akins in a review of mechanical prostheses.[28] That same year, a report from the University of Padua, describing cases of acute failure of various mechanical prostheses because of thrombosis and fibrous pannus formation, included mention of thrombosis in a patient after AVR with use of a Pemco-Cartwright prosthesis.[29] Ball variance was also problematic in this valve (Fig. 4).

Fig. 3 *Photograph shows a Pemco-Cartwright valve, with an incomplete 4-strut cage and a Silastic ball.*



Fig. 4 *Photograph shows ball variance due to lipid absorption by the ball of a Pemco-Cartwright valve.*

Magovern-Cromie Valve (1962)

Early in the caged-ball valve era, prosthetic valve replacement was considered extremely risky because of the technical problems associated with valve insertion and the need for prolonged CPB, which increased the risk of myocardial ischemia. The Magovern-Cromie valve, introduced in 1962, was designed to overcome these problems. The prototype consisted of a closed stainless-steel cage, a silicone ball, and a unique, rotatable inner basal ring containing 9 titanium pins for fixation (Fig. 5). That unique feature made possible quick, sutureless implantation. The prototype was subsequently modified to include an open titanium cage and a radiopaque ball. Although production ceased in 1980, the Magovern-Cromie valve continued to be used and had favorable 25-year results.[15,30] Of note, the concept of sutureless fixation, which Hufnagel had already attempted and which was applied in the Magovern-Cromie valve, would be revitalized and successfully applied to bioprosthetic AVs 50 years later.[31]

Smeloff-Cutter Valve (1966)

The Smeloff-Cutter prosthesis, introduced commercially in 1966, had a unique double-caged design very different from that of the Harken-Soroff valve (Fig. 6).[32] It consisted of a double open cage of bare titanium and a silicone rubber ball. The clearance between cage and ball was designed to produce an antithrombotic washing effect. The valve's reduced height limited its protrusion into the left ventricle during MVR; its smaller ball reduced the risk of aortic wall contact and the consequent prosthetic stenosis that had been observed with the Starr-Edwards valve.[32] Nevertheless, ball variance led to the use of cured silicone balls in subsequent models. Despite the valve's allegedly superior hemodynamic performance and ability to be used without

Fig. 5 *Photograph shows a Magovern-Cromie valve, with a stainless-steel cage, a silicone ball, and a sutureless fixation ring.*

Reproduced with permission from the National Museum of American History of the Smithsonian Institute, Washington, DC.

anticoagulation therapy,[33] its open cage was in several cases considered responsible for endocardial perforation by the strut tips and entanglement of the struts in papillary muscle remnants during MVR.[14,34] Although the Smeloff-Cutter prosthesis was used clinically until the late 1980s,[15] data on long-term outcomes are lacking. However, there are individual reports of Smeloff-Cutter valves that were still functioning 43 years after MVR and 49 years after AVR.[35,36] A combined total of approximately 72,000 of the valves were implanted in the aortic and mitral positions.[15]

Fig. 6 *Photograph shows a Smeloff-Cutter valve, with a titanium double open cage and a silicone rubber ball.*

Reproduced with permission from the National Museum of American History of the Smithsonian Institute, Washington, DC.

Fig. 7 *Photograph shows a DeBakey-Surgitool valve, with a titanium cage and a hollow pyrolytic carbon ball.*

Reproduced with permission from the National Museum of American History of the Smithsonian Institute, Washington, DC.

DeBakey-Surgitool Valve (1967)

The DeBakey-Surgitool valve had a closed caged-ball design that for the first time incorporated pyrolytic carbon, an extremely strong, thromboresistant, biocompatible material (Fig. 7).[37] The substance comprised the valve's hollow plastic ball and covered its 3 bare titanium struts.[37] The valve's plastic, polyethylene sewing ring was intended to prevent endothelial covering and avoid leakage during diastole. A major issue with this valve was strut wear and rupture due to repeated contact of the harder pyrolytic carbon ball with the softer titanium cage, leading in some cases to ball embolization (Fig. 8).[11] Nevertheless, extended durability of greater than 30 years has been reported.[38] An estimated 1,200 DeBakey-Surgitool prostheses were implanted in the aortic position until 1984, when production ceased.[15]

Braunwald-Cutter Valve (1968)

The Braunwald-Cutter device had an open titanium cage with 3 Dacron-covered struts, an orifice covered

Fig. 8 *Photograph shows a fatal embolism of the ball of a DeBakey-Surgitool valve after cage rupture. On gross examination, the ball was found at the aortic bifurcation.*

by an ultrathin polypropylene mesh, and a silicone rubber ball (Fig. 9). The extensive use of cloth coverings was the result of continuing efforts to reduce thrombogenicity by promoting growth of thin layers of autologous tissue.[39] Laboratory findings had indicated that thrombogenicity was influenced by the type, geometry, and thickness of the cloth used.[39] The Braunwald-Cutter valve was first implanted clinically in 1968. Early results were encouraging, despite a series of postoperative prosthesis-related complications including ball escape and strut cloth wear.[40,41] Approximately 5,000 Braunwald-Cutter prostheses were implanted, until production ceased in 1979.[40,41] In isolated cases, the valve has functioned beyond 40 years.[42]

Conclusion

The most popular caged-ball prostheses were safe, durable, and minimally thrombogenic, the result of 6 decades of efforts to identify and optimize materials and to understand and correct problems in design and function. Cage and ball wear were mitigated by incorporating materials that reduced erosion of either component by the other. The risk of thromboembolism, a major drawback of all caged-ball prostheses necessitating lifelong anticoagulation, was greatly attenuated by improvements in design, biocompatibility, and hemodynamic performance. Meanwhile, knowing the characteristics and peculiarities of these durable prostheses remains important, because many recipients still survive. After 60 years, the caged-ball valve continues to benefit new generations through the history of its development and the extremely reliable cardiac valve substitutes that have resulted.

Fig. 9 *Photograph shows a Braunwald-Cutter valve, with an open, Dacron-covered titanium cage and a silicone rubber ball.*

Reproduced with permission from the Museum of Medical History, Sierra Sacramento Valley Medical Society and the Bioengineering Department, California State University, Sacramento, California.

Published: 7 April 2022

References

1. Harken DE, Soroff HS, Taylor WJ, Lefemine AA, Gupta SK, Lunzer S. Partial and complete prostheses in aortic insufficiency. J Thorac Cardiovasc Surg 1960;40:744-62.
2. Starr A, Edwards ML. Mitral replacement: clinical experience with a ball-valve prosthesis. Ann Surg 1961;154(4):726-40.
3. Khan MN. The relief of mitral stenosis: an historic step in cardiac surgery. Tex Heart Inst J 1996;23(4):258-66.
4. Hufnagel CA, Harvey WP. The surgical correction of aortic regurgitation: preliminary report. Bull Georgetown Univ Med Cent 1953;6(3):60-1.
5. Hufnagel CA, Gomes NM. Late follow-up of ball-valve prostheses in the descending thoracic aorta. J Thorac Cardiovasc Surg 1976;72(6):900-9.
6. Gross RE. Coarctation of the aorta: surgical treatment of 100 cases. Circulation 1950;1(1):41-55.
7. Lillehei CW, Cohen M, Warden HE, Varco RL. The direct-vision intracardiac correction of congenital anomalies by controlled cross circulation: results in thirty-two patients with ventricular septal defects, tetralogy of Fallot, and atrioventricularis communis defects. Surgery 1955;38(1):11-29.
8. Gibbon HJ Jr. The development of the heart-lung apparatus. Am J Surg 1978;135(5):608-19.
9. Swan H, Maaske C, Johnson M, Grover R. Arterial homografts. II. Resection of thoracic aortic aneurysm using a stored human arterial transplant. AMA Arch Surg 1950;61(4):732-7.
10. Crafoord C, Ejrup B, Gladnikoff H. Coarctation of the aorta. Thorax 1947;2(3):121-52.
11. Fishbein MC, Roberts WC. Late postoperative anatomic observations after insertion of Hufnagel caged-ball prostheses in descending thoracic aorta. Chest 1975;68(1):6-11.
12. DeWall RA, Qasim N, Carr L. Evolution of mechanical heart valves. Ann Thorac Surg 2000;69(5):1612-21.
13. Matthews AM. The development of the Starr-Edwards heart valve. Tex Heart Inst J 1998;25(4):282-93.
14. Lefrak EA, Starr A. Current heart valve prostheses. Am Fam Physician 1979;20(3):93-9.
15. Gott VL, Alejo DE, Cameron DE. Mechanical heart valves: 50 years of evolution. Ann Thorac Surg 2003;76(6): S2230-9.
16. Starr A, Edwards ML. Mitral replacement: the shielded ball valve prosthesis. J Thorac Cardiovasc Surg 1961;42:673-82.
17. Hodam R, Starr A, Herr R, Pierie WR. Early clinical experience with cloth-covered valvular prostheses. Ann Surg 1969;170(3):471-82.
18. Shah A, Dolgin M, Tice DA, Trehan N. Complications due to cloth wear in cloth-covered Starr-Edwards aortic and mitral valve prostheses--and their management. Am Heart J 1978;96(3):407-14.
19. Hylen JC, Hodam RP, Kloster FE. Changes in the durability of silicone rubber in ball-valve prostheses. Ann Thorac Surg 1972;13(4):324-9.
20. Kahn P, Carmen R. Reduction of ball variance in silicone rubber occluders. Ann Thorac Surg 1989;48(3 Suppl):S10-1.
21. Starr A, Grunkemaier GL. Durability of the Starr-Edwards heart valve: early decisions led to successful results. Tex Heart Inst J 2016;43(1):2-3.

22. Gödie OL, Fischlein T, Adelhard K, Nollert G, Klinner W, Reichart B. Thirty-year results of Starr-Edwards prostheses in the aortic and mitral position. Ann Thorac Surg 1997;63(3):613-9.
23. Saxena P, Bonnichsen CR, Greason KL. Starr-Edwards aortic valve: forty-four years old and still working! J Thorac Cardiovasc Surg 2013:146(4):e21-2.
24. Amrane M, Soulat G, Carpentier A, Jouan J. Starr-Edwards aortic valve: 50+ years and still going strong: a case report. Eur Heart J Case Rep 2017;1(2):ytx014.
25. Ata Y, Turk T, Eris C, Yalcin M, Ata F, Ozyazicioğlu A. Extended durability of a cloth-covered Star-Edwards [sic] caged ball prosthesis in aortic position. Case Rep Med 2009;2009:165858.
26. Cartwright RS, Giacobine JW, Ratan RS, Ford WB, Palich WE. Combined aortic and mitral valve replacement. J Thorac Cardiovasc Surg 1963;45:35-46.
27. Cartwright RS, Palich WE, Ford WB, Giacobine JW, Zubritzky SA, Ratan RS. Combined replacement of aortic and mitral valves. an original transatrial approach to the aortic valve. JAMA 1962;180:6-10.
28. Akins CW. Mechanical cardiac valvular prostheses. Ann Thorac Surg 1991;52(1):161-72.
29. Rizzoli G, Guglielmi C, Toscano G, Pistorio V, Vendramin I, Bottio T, et al. Reoperations for acute prosthetic thrombosis and pannus: an assessment of rates, relationship and risk. Eur J Cardiothorac Surg 1999;16(1):74-80.
30. Magovern GJ, Liebler GA, Park SB, Burkholder JA, Sakert T, Simpson KA. Twenty-five-year review of the Magovern-Cromie sutureless aortic valve. Ann Thorac Surg 1989;48(3 Suppl):S33-4.
31. D'Onofrio A, Salizzoni S, Filippini C, Tessari C, Bagozzi L, Messina A, et al. Surgical aortic valve replacement with new-generation bioprostheses: sutureless versus rapid-deployment. J Thorac Cardiovasc Surg 2020;159(2):432-42.e1.
32. Seningen RP, Bulkley BH, Roberts WC. Prosthetic aortic stenosis: a method to prevent its occurrence by measurement of aortic size from preoperative aortogram. Circulation 1974;49(5):921-4.
33. Begonia Gometza MD, Duran CMG. Ball valve (Smeloff-Cutter) aortic valve replacement without anticoagulation. Ann Thorac Surg 1995;60(5):1312-6.
34. Ibarra-Pérez C, Rodriguez-Trujillo F, Pérez-Redondo H. Engagement of ventricular myocardium by struts of mitral prosthesis: fatal complication of use of open-cage cardiac valves. J Thorac Cardiovasc Surg 1971;61(3):403-4.
35. Head SJ, Ko J, Singh R, Roberts WC, Mack MJ. 43.3-year durability of a Smeloff-Cutter ball-caged mitral valve. Ann Thorac Surg 2011;91(2):606-8.
36. Chalkley RA, Kim CW, Choi JW, Roberts WC, Schussler JM. Smeloff-Cutter mechanical prosthesis in the aortic position for 49 years. Am J Cardiol 2019;124(3):457-9.
37. Beiras-Fernandez A, Oberhoffer M, Kur F, Kaczmarek I, Vicol C, Reichart B. 34-year durability of a DeBakey Surgitool mechanical aortic valve prosthesis. Interact Cardiovasc Thorac Surg 2006;5(5):637-9.
38. Bokros JC. Carbon in prosthetic heart valves. Ann Thorac Surg 1989;48(3 Suppl):S49-50.
39. Hannah H 3rd, Bull B, Braunwald NS. The development of an autogenous tissue covering on prosthetic heart valves: effect of warfarin and dextran. Ann Surg 1968;168(6):1075-8.
40. Blackstone EH, Kirklin JW, Pluth JR, Turner ME, Parr GV. The performance of the Braunwald-Cutter prosthetic valve. Ann Thorac Surg 1977;23(4):302-18.
41. Jonas RA, Barratt-Boyes BG, Kerr AR, Whitlock RML. Late follow-up of the Braunwald-Cutter valve. Ann Thorac Surg 1982;33(6):555-61.
42. Jiménez-Rodríguez GM, Criales-Vera S, Juárez-Peñaloza MA, González-Tapia LA, Chaire-Hernández M. Normal function of a 43-year-old Braunwald-Cutter heart valve. Oxf Med Case Reports 2018;2018(2):omx107.